Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

TNFα inhibitor treatment tied to increase in body weight, BMI in psoriasis patients

18 Dec 2019

Treatment with tumour necrosis factor-alpha (TNFα) inhibitor may likely lead to an increase in body weight and body mass index (BMI) in patients with psoriasis, whereas treatment with anti-interleukin (IL)-12/23 and IL-17 biologics does not, results of a recent systematic review and meta-analysis have shown.

“Previous studies have suggested that biologic therapy for psoriasis might relate to body weight gain,” the investigators noted.

This systematic review and network meta-analysis was carried out to assess the changes in body weight and BMI in patients with psoriasis treated with biologics. The databases of Medline, Embase and Cochrane Central Register of Controlled Trials were searched for relevant studies on 1 March 2019. The risk of bias was evaluated using the Newcastle-Ottawa scale.

Six studies including a combined total of 862 psoriasis patients met the eligibility criteria. Treatment with TNFα inhibitors appeared to result in a significant increase in body weight (mean difference, 1.40 kg, 95 percent confidence interval [CI], 0.88–1.93 kg) and in BMI (mean difference, 0.39 kg/m2, 95 percent CI, 0.24–0.54 kg/m2) as compared with conventional systemic therapies.

On the other hand, patients treated with anti-IL-12/23 or anti-IL-17 biologics did not show a significant increase in their body weight or BMI.

“This association should be considered before initiating biologics for overweight and obese patients,” the investigators said.

This study had certain limitations. For instance, only one study had findings on body weight and BMI for patients treated with anti-IL-17 biologic.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.